Companies
Cellares
operates the Cell Shuttle automated cell-therapy manufacturing platform within its "smart factory" (IDMO) model, with a documented case of first-patient dosing on product manufactured entirely on the platform for a partner's cell therapy, positioned as an alternative to conventional CDMO manual manufacturing.
- Country
- United States
US
Coverage
| EU | US | |
|---|---|---|
| automation-robotics | ✓ | ✓ |
Regulatorsfdaema
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $327 million total Series D funding | cellares.com |
| Capacity | Up to 2,500 batches per year per Cell Shuttle unit; Smart Factory in Bridgewater has capacity for 20,000–100,000 doses per year; Smart Factory in South San Francisco has capacity for 2,000–10,000 doses per year | cellares.com |
| Certification | cGMP-compliant Cell Shuttle platform | cellares.com |
| Regulatory approval | FDA Advanced Manufacturing Technology (AMT) designation for Cell Shuttle; FDA clearance of IND amendment for rese-cel clinical manufacturing | cellares.com |
| Production site | South San Francisco, CA; Bridgewater, NJ; Leiden, Netherlands; Kashiwa City, Japan | cellares.com |
| Headcount | Approximately 279–305 employees medium confidence | getlatka.com |
| Revenue | $82 million (2025 ARR) medium confidence | getlatka.com |
Independent sources: getlatka.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Automated cell culture systems | automation-robotics | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.